Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 12, Issue 6, 2005, Pages 530-534

  Lindgren, Peter ^a,b   Borgström, Fredrik ^a   Stålhammar, Jan ^c   Alemao, Evo ^d   Yin, Donald Donping ^d   Jönsson, Linus ^a,b  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Goal attainment; Hypercholesterolaemia; Lipid lowering

Indexed keywords

ANTILIPEMIC AGENT; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; CONFIDENCE INTERVAL; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; HOSPITAL PATIENT; HYPERLIPIDEMIA; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; INPATIENTS; LIPIDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME;

EID: 33644875925     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/00149831-200512000-00003     Document Type: Article

References (14)

1. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321:1322-1325.
2. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158:1238-1244.
3. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357 (9261):995-1001.
4. Hilleman DE, Monaghan MS, Ashby CL, Mashni JE, Woolley K, Amato CM. Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease. Pharmacotherapy 2001; 21:1415-1421.
5. Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001; 6:129-135.
6. Centre for Epidemiology. The Swedish Hospital Discharge Register: The National Board of Health and Welfare, 1999.
7. Centre for Epidemiology. The Cause of Death Register: The National Board of Health and Welfare, 2001.
8. Swedish Medical Product Agency. Behandling med lipidsänkande läkemedel vid prevention av hjärtkärlsjukdom (Treatment guidelines for the use of lipid lowering agents in the prevention of heart disease, in Swedish). Uppsala, 2003.
9. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
12. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361 (9364):1149-1158.
13. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
14. The Long-Term Intervention with Pravastatin Group in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.